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Abstract
Background: To fulfill the model based drug development, the very first step is usually a model establishment
from published literatures. Pharmacokinetics model is the central piece of model based drug development. This
paper proposed an important approach to transform published non-compartment model pharmacokinetics (PK)
parameters into compartment model PK parameters. This meta-analysis was performed with a multivariate
nonlinear mixed model. A conditional first-order linearization approach was developed for statistical estimation
and inference.
Results: Using MDZ as an example, we showed that this approach successfully transformed 6 non-compartment
model PK parameters from 10 publications into 5 compartment model PK parameters. In simulation studies, we
showed that this multivariate nonlinear mixed model had little relative bias (<1%) in estimating compartment
model PK parameters if all non-compartment PK parameters were reported in every study. If there missing non-
compartment PK parameters existed in some published literatures, the relative bias of compartment model PK
parameter was still small (<3%). The 95% coverage probabilities of these PK parameter estimates were above 85%.
Conclusions: This non-compartment model PK parameter transformation into compartment model meta-analysis
approach possesses valid statistical inference. It can be routinely used for model based drug development.
Background
In recent decades, a new drug requires an average of 15
years and approaching a billion dollars in research and
development [1]. Unfortunately, only one in 10 drugs
that enter clinical testing receives eventual FDA
approval [2,3]. Scientists have become increasingly
mechanistic in their approach to drug development [4].
The recent ability to integrate genetic mutations and
altered protein expression to pharmacokinetics (PK) and
pharmacodynamic (PD) models allow a deeper under-
standing of the mechanisms of disease and therapies
that are genuinely targeted [5-8]. In 2004, the FDA
released a report entitled: “Innovation or Stagnation,
Challenge and Opportunity on the Critical Path to New
Medical Products” [9]. Among its six general topic
areas, three of them emphasized the importance of com-
putational modeling and bioinformatics in biomarker
development and streamlining clinical trials [10,11]. In
multiple follow-up papers, clinical researchers, experi-
mental biologists, computational biologists, and biosta-
tisticians from both academia and industry all supported
the FDA leadership in this critical path, and pointed out
the challenges and opportunities of the PK/PD model
based approach in drug development [12][13-15].
Pharmacokinetics model is the central piece of model
based drug development. Almost all of the published PK
data were summarized without fitting a compartment
model. They are usually called non-compartment model
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tion curve (AUC) is calculated from drug plasma con-
centration data based on trapezoid-rule [16]; clearance
is calculated from dose and AUC; Cmax and Tmax are
calculated from concentrations and their associated time
points; terminal half-life is usually calculated from the
last two to four sampling time-points directly; and etc.
All these parameters cannot be used directly in a com-
partment model, and their transformation to compart-
ment model PK parameters is essential.
Methods
Non-Compartment Model to One-Compartment Model
Transformation
When a drug follows a one-compartment model of oral
dose (1), the following non-compartment model PK
parameters, w =( AUC, Tmax, T1/2), are necessary
to recover the one-compartment model parameters,
b =( ka, ke, V).
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where, F is an assumed known bioavailability, and
dose denotes the oral dose. If however, only oral clear-
ance, CLpo is reported, instead of AUC,t h e nCL po =V
×K e. On the other hand, when dosing is through IV,
only w =( AUC, T1/2), are necessary to recover the one
compartment (3), with b =( ke, V). The transformation
formulas are defined in (4).
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Similarly, if CLiv is reported, instead of AUC,t h e n
CLIV =V×k e. These one-compartment-model and non-
compartment model parameters and transformation
were defined and discussed in great detail by [16].
Non-Compartment Model to Two-Compartment Model
Transformation
If a drug’s pharmacokinetics follows a two-compartment
model with oral dose (5), the following non-compart-
ment model PK parameters, w =( Vd, AUC, Tmax, CLiv,
T1/2,slow, T1/2,fast), are necessary to recover the two-com-
partment model parameters, b =( ka, ke, V1, k12, k21).
Their transformations are defined in (6).
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If a drug’s pharmacokinetics follows a two-compart-
ment model with IV dose (7), the following non-com-
partment model PK parameters, w =( Vd, AUC, CLiv,
T1/2, slow, T1/2, fast), are necessary to recover the two-
compartment model parameters, b =( ke,V1, k12, k21).
Their transformations are defined in (8).
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A Multivariate Nonlinear Mixed Effect Model
(Model Specification)
Based on the multiple transformation equations between
non-compartment model PK parameters and one or two
compartment models, a multivariate nonlinear mixed
effect model is established to estimate the population
level PK parameters and their between study variances.
Denote wjk as the observed j th non-compartment PK
parameter (j=1,…, Jk) from study k (k=1,..,K). Please note
that not every study published all of the non-compart-
ment parameters, hence Jk varies from study to study. bk
is the study level compartment-model PK parameter
vector, and gj (bk)r e p r e s e n t st h et r a n sformation func-
tion. Because non-compartment model PK parameter,
wjk, is usually published in the form of a sample mean,
model (9) shows that its variance is  jk n
2 / ,w h e r e
 j
2is the within study variance (assumed to be homoge-
neous across studies), and nk is study k sample size
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Model (9) also shows that the observed non-compart-
ment model parameters, ( , ,..., ) ww w kk J k k 12 ,a r e
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Page 2 of 7independent. This is a multivariate nonlinear regression
model.
Study level compartment model parameter bk is
assumed to follow multivariate normal distribution (10),
in which µ is the population PK parameter vector and
Ωk is its general covariance matrix.
pM V N kk k (|) ~ ( ,)  ΩΩ (10)
The joint likelihood of population/subject parameters
and their covariance is shown in equation (11).
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where W = ( ,..., ) ww JK
T
K 11 is a J×1 ( JJ k
k
=∑ )
observed non-compartment model PK parameter
vector; XX X = ( ,..., ) 1
T
K
TT is a J×p indicator matrix, and Xk
is a Jk×p matrix indicating the corresponding transforma-
tion function; g(.) is a p×1 transformation function vector;
   = ( , ,..., ) 12
TT
K
TT is a study level compartment-
model PK parameter vector; ∑= ∑ ∑ {} diag K 1,..., is a
diagonal J×J covariance matrix for W, and
ZI I I = ( , ,..., ) 12 K
T ; ZI I I = ( , ,..., ) 12 K
T is a Kp×p design
matrix relating study-specific parameter b to population
parameter µ,a n dIk is an identity matrix; and
ΩΩ Ω = diag K { ,..., } 1 is a Kp×Kp covariance matrix for
study-specific parameter b.
This multivariate nonlinear mixed model (11) is differ-
ent from the conventional univariate nonlinear mixed
model [17] structurally in the additional design matrix
X in front of the nonlinear function ( i.e. transformation
function g(.)). Model (11) is a meta-analysis approach,
in which sample mean non-compartment model PK
parameters are formulated. Among the existing non-
linear mixed model meta-analysis literatures, some dealt
with the subject-level data from multiple studies [18,19];
the others dealt with sample mean drug concentration
data [20,21]; and none of them discussed the meta-ana-
lysis on summarized PK parameters through the non-
compartment model.
A Multivariate Nonlinear Mixed Effect Model
(Estimation and Inference)
As a conditional first order linearization approach pro-
vides the least biased estimate in estimating the PK
parameter with comparable efficiency [22,23]), it is cho-
sen as the estimation approach for this multivariate
nonlinear mixed model. This conditional first order line-
arization approach was firstly introduced by Lindstrom
and Bates [24]. We revise their derivation based on our
special meta-analysis multivariate nonlinear mixed
model (11). This two-step estimation scheme is
described as following.
Step 1: given the current estimate of variance
component ˆ Ωand ˆ ∑ , minimize the following objective
function, L1, with respect to (b,µ ).
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Computationally, minimizing L1 on (b,µ )i sa ni t e r a -
tive process. Within each iteration, a linearization is
applied to Xg(b) with respect to b, and a linear mixed
model (13) is fitted [24].
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Step 2: given the current estimate,(,) 
∧ ∧ , minimize
the following objective function, L2 , with respect to θ,
which is the variance component parameter vector in
(Ω, Σ), and it is of dimension q.
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This L2 likelihood function is the restricted maximum
likelihood for variance component estimates. The scores
and the elements of information matrix for θ are
defined in (17).
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algorithm. An alternative derivation of this two-step first
order linearization is through a second order Laplace’s
approximation [25-27].
Results
Midazolam Non-Compartment Model Parameters
to Compartment Model Parameters Transformation
Data Analysis
After extensive literature search, 10 midazolam pharma-
cokinetics studies were identified, and their published
non-compartment PK parameters are reported in Table
1. (Cmax, AUC, T1/2,slow) were reported with high fre-
quencies, i.e. 8 to 10 out 10 publications. T1/2,fast was
published only twice. Both Vd and CLiv were published
5 to 6 times.
A multivariate nonlinear mixed effect model is fitted
to these published non-compartment PK parameters to
estimate their compartment model PK parameters. The
NONMEM code is reported in Appendix I. In this
meta-analysis, between study variances are assumed for
(V1, ka, k e). (k12, k21)w e r ea s s u m e dt ob et h ef i x e d
effects across different studies without random effects,
because only two papers published the MDZ distribu-
tion information, i.e. T1/2,fast. All of the non-compart-
ment model parameters were log-transformed. They
were assumed to have the same within study variance in
log-scale (i.e. same coefficient of variance in the raw
scale). All of the compartment model PK parameters
were also log-transformed, and their between study
standard deviations can be interpreted as coefficient of
variance in raw scale.
Figure 1 displays the convergence plots for all five
compartment PK parameters (V1, ka, k12, k21, ke). The x-
axes are these PK parameters’ domain, and the y-axes
are the likelihood function (13). It appears that all these
PK parameter estimates reach maximum likelihood, and
we don’t observe any non-identifiable parameters.
Table 2 reported the PK parameter estimates.V 1 =3 3
L, ka =0 . 6 81 / h ,k12 =0 . 3 31 / h ,k21 =0 . 2 71 / h ,a n d
ke = 0.67 (1/h). Please notice that V1 has very small
between study variances, CV= 10%; ka has high between
study variance, CV = 84%; and ke’s variation is moder-
ate, CV = 23%. On the other hand, the within-study var-
iation of reported non-compartment PK parameters is
moderate, CV = 27%.
Simulation Studies
Simulation Schemes
The primary concern of this non-compartment PK para-
meter transformation to compartment model PK para-
meter is the bias of PK parameter estimates. Two
simulation studies were designed to investigate this pro-
blem. In the first simulation, every non-compartment
PK parameter was observed for each study. In the sec-
ond simulation, the same amount of missing data as our
MDZ example was assumed to be present.
In each simulation, 1000 simulated data sets were gen-
erated. Each data set had 10 studies, and each study
reported either all (Cmax, AUC, T1/2,slow, T1/2,fast, Vd,
CLiv) in simulation 1, or a partial amount of (Cmax,
AUC, T1/2,slow, T1/2,fast, Vd, CLiv) in simulation 2. These
non-compartment model PK parameters were simulated
based on the two-compartment model transformation
relationship (5) and (6), their meta-analysis multivariate
nonlinear mixed model (9) and (10), and MDZ PK para-
meter estimates and variances from Table 2.
Simulation Evaluation Criteria
Both fixed effect and variance components were evalu-
ated in the simulation studies. The bias was calculated
as the relative bias: abs(true-est)/est; and their 95% cov-
erage probabilities were also reported based on model
based 95% confidence interval. Coverage probabilities
outside of (92.93, 97.07) were highlighted. The half-
width of this interval is three times the binomial stand
error, which is [(95%)(5%)/1000]
1/2=0.6892%. Standard
error was also reported based on 1000 simulation
results.
Simulation 1 (All Reported and No Missing Data)
Table 3 reported the simulation results. Among fixed
effects, all of the relative biases are less than 1%. (V1,k a,
k e) had lower 95% coverage probabilities than (K12, K21)
did, because (V1, ka, k e) were assumed to have between
study variances, but (K12, K21)d i d n ’t have. Therefore,
the low 95% coverage probability was probably due to
the under estimated standard error. On the other hand,
the biases of between study variance estimates were
between 5% and 12.8%, though their 95% CP were all
around 95%.
Simulation 2 (With Missing Data)
Table 4 reported the simulation results. Among fixed
effects, all of the relative biases can be as high as 2.84%
(i.e. ke). All of their 95% coverage probabilities were out-
side of the normal range, (92.93%, 97.07%). The low
Table 1 Summary of Published Non-Compartment Model
Midazolam Pharmacokinetics Parameters
Non-Compartment PK Parameters Reported Missed
Cmax 91
AUC 10 0
Tmax 73
T1/2,fast 28
T1/2,slow 82
Vd 55
CLiv 46
There are totally 10 studies available from publications. This table shows
the number of reported and missed records for the sample means of
non-compartment PK parameters among those 10 studies.
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Page 4 of 7Figure 1 Convergence plots for five two-compartment midazolam pharmacokinetics parameters. The x-axes are log-transformed PK parameters,
and y-axes are the log-likelihood functions. The dots on the top represent the maximum likelihood estimates.
Table 2 Midazolam Compartment Model Pharmacokinetics Parameter Estimates
Compartment Model PK Parameters Non-Compartment Model to Compartment Model Transformation
Fixed-Effect
log-scale raw-scale Between Study CV*
V1 3.5 33.11 10%
ka 0.68 1.97 84%
k12 -1.1 0.33 -
k21 -1.32 0.27 -
ke -0.403 0.67 23%
Within-Study CV** 27%
These compartment model PK parameters are estimated from reported non-compartment model PK parameters. *These are between-study variances for
compartment model PK parameters. **This is the within-study variance for all non-compartment PK parameters.
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Page 5 of 7coverage of (V1, ka, k e) was probably due to their
between subject variations; and the low coverage prob-
ability for k12 and high coverage for k21 were probably
due to the missing data. As in the MDZ example, T1/2,
fast had only 2 out of 10 papers published. On the other
hand, the biases of between study variance estimates
were between 3.6% and 9.8%, though their 95% CP were
within (92.93%, 97.07%).
Conclusions
This paper proposed an important approach to transform
published non-compartment model pharmacokinetics
parameters into compartment model PK parameters.
This meta-analysis was performed with a multivariate
nonlinear mixed model. A conditional first-order lineari-
zation approach was developed for statistical estimation
and inference, and it was implemented in R. Using MDZ
as an example, we have shown that this approach trans-
formed 6 non-compartment model PK parameters from
10 publications into 5 compartment model PK para-
meters, and the conditional first order linearization
approach converged to the maximum likelihood. In the
follow-up simulation studies, we have shown that our
meta-analysis multivariate nonlinear mixed model had
little relative bias (<1%) in estimating compartment
model PK parameters if all non-compartment PK para-
meters were reported in every study. If there existed
missing non-compartment PK parameters, the relative
bias of compartment model PK parameter was still small
(<3%). The 95% coverage probabilities of these PK para-
meter estimates were usually above 85% or more. There-
fore, this approach possesses adequately valid inference.
Although this paper only showed the transformation
performance of non-compartment model PK parameters
to two-compartment model with oral dose PK para-
meters, we think it is probably the most complicated
case among published drug PK studies. One compart-
ment models and two-compartment model with IV dose
have simpler transformation function and less computa-
tional expense.
Sometimes, not all of the required non-compartment
model PK parameters are available in the literature.
Whether it is feasible to transform these data into com-
partment model is an interesting and important question.
In this paper, MDZ was chosen as an example. Because
MDZ has been a well studied probe drug, its published
non-compartment model PK parameters were expected to
be rich. Other rarely studied drugs may not have all these
published information, and their compartment model
developments from literature need further investigations.
Table 3 Simulation Results with No Missing Data
Estimate
TRUE(log-scale) Mean SE RelativeBias (%) 95% CP
V1 3.5 3.505 0.110 0.14 0.89
ka 0.68 0.680 0.115 0.02 0.87
Fixed-Effect ke -0.403 -0.397 0.112 0.75 0.89
k12 -1.1 -1.097 0.088 0.24 0.93
k21 -1.32 -1.322 0.053 0.15 0.99
V1 0.09 0.083 0.045 8.05 0.97
Between Study Variance ka 0.09 0.078 0.053 12.8 0.93
ke 0.09 0.085 0.045 5.33 0.96
Sigma
2 0.01 0.01 0.003 4.43 0.95
Table 4 Simulation Results with Missing Data
Estimate
TRUE(log-scale) Mean SD RelativeBias (%) 95% CP
V1 3.5 3.494 0.129 0.17 0.92
ka 0.68 0.672 0.159 1.13 0.87
Fixed-Effect ke -0.403 -0.389 0.141 2.84 0.90
k12 -1.1 -1.09 0.172 0.59 0.84
k21 -1.32 -1.323 0.070 0.19 0.99
V1 0.09 0.081 0.052 9.82 0.98
Between Study Variance ka 0.09 0.082 0.066 9.43 0.95
ke 0.09 0.087 0.055 3.60 0.97
Sigma
2 0.01 0.01 0.003 13.9 0.96
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